Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth (Status and Outlook) 2025-2031

September 2025 | 105 pages | ID: G6F249B5C1D0EN
LP Information

Abstracts

According to this study, the global NTRK Fusion Gene Positive Advanced Solid Tumor market size will reach US$ million by 2031.

United States market for NTRK Fusion Gene Positive Advanced Solid Tumor is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for NTRK Fusion Gene Positive Advanced Solid Tumor is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for NTRK Fusion Gene Positive Advanced Solid Tumor is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key NTRK Fusion Gene Positive Advanced Solid Tumor players cover Bayer, Teva Pharmaceuticals, Empire Genomics, SeraCare Life Sciences, F. Hoffmann-La Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “NTRK Fusion Gene Positive Advanced Solid Tumor Industry Forecast” looks at past sales and reviews total world NTRK Fusion Gene Positive Advanced Solid Tumor sales in 2024, providing a comprehensive analysis by region and market sector of projected NTRK Fusion Gene Positive Advanced Solid Tumor sales for 2025 through 2031. With NTRK Fusion Gene Positive Advanced Solid Tumor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NTRK Fusion Gene Positive Advanced Solid Tumor industry.

This Insight Report provides a comprehensive analysis of the global NTRK Fusion Gene Positive Advanced Solid Tumor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on NTRK Fusion Gene Positive Advanced Solid Tumor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NTRK Fusion Gene Positive Advanced Solid Tumor market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NTRK Fusion Gene Positive Advanced Solid Tumor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NTRK Fusion Gene Positive Advanced Solid Tumor.

This report presents a comprehensive overview, market shares, and growth opportunities of NTRK Fusion Gene Positive Advanced Solid Tumor market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Therapeutics
• Diagnostics

Segmentation by Application:

• Hospitals and Clinics
• Cancer Centers
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Bayer
• Teva Pharmaceuticals
• Empire Genomics
• SeraCare Life Sciences
• F. Hoffmann-La Roche
• NeoGenomics Laboratories
• Glaxosmithkline
• OncoDNA
• Merck & Co.
• Daiichi Sankyo
• S Deciphera Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2020-2031)
  2.1.2 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for NTRK Fusion Gene Positive Advanced Solid Tumor by Country/Region (2020, 2024 & 2031)
2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Segment by Type
  2.2.1 Therapeutics
  2.2.2 Diagnostics
2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
  2.3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2020-2025)
2.4 NTRK Fusion Gene Positive Advanced Solid Tumor Segment by Application
  2.4.1 Hospitals and Clinics
  2.4.2 Cancer Centers
  2.4.3 Others
2.5 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
  2.5.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2020-2025)

3 NTRK FUSION GENE POSITIVE ADVANCED SOLID TUMOR MARKET SIZE BY PLAYER

3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Player
  3.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Player (2020-2025)
  3.1.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Player (2020-2025)
3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 NTRK FUSION GENE POSITIVE ADVANCED SOLID TUMOR BY REGION

4.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025)
4.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Annual Revenue by Country/Region (2020-2025)
4.3 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2020-2025)
4.4 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2020-2025)
4.5 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2020-2025)
4.6 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025)
5.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025)
5.3 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025)
6.2 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025)
6.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025)
7.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025)
7.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor by Region (2020-2025)
8.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025)
8.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL NTRK FUSION GENE POSITIVE ADVANCED SOLID TUMOR MARKET FORECAST

10.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2026-2031)
  10.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2026-2031)
  10.1.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.1.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.1.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.1.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Country (2026-2031)
  10.2.1 United States Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.2.2 Canada Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.2.3 Mexico Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.2.4 Brazil Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2026-2031)
  10.3.1 China NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  10.3.2 Japan Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.3.3 Korea Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.3.4 Southeast Asia Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.3.5 India Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.3.6 Australia Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Country (2026-2031)
  10.4.1 Germany Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.4.2 France Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.4.3 UK Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.4.4 Italy Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.4.5 Russia Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2026-2031)
  10.5.1 Egypt Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.5.2 South Africa Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.5.3 Israel Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  10.5.4 Turkey Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.6 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Type (2026-2031)
10.7 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market NTRK Fusion Gene Positive Advanced Solid Tumor Forecast

11 KEY PLAYERS ANALYSIS

11.1 Bayer
  11.1.1 Bayer Company Information
  11.1.2 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.1.3 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Bayer Main Business Overview
  11.1.5 Bayer Latest Developments
11.2 Teva Pharmaceuticals
  11.2.1 Teva Pharmaceuticals Company Information
  11.2.2 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.2.3 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Teva Pharmaceuticals Main Business Overview
  11.2.5 Teva Pharmaceuticals Latest Developments
11.3 Empire Genomics
  11.3.1 Empire Genomics Company Information
  11.3.2 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.3.3 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Empire Genomics Main Business Overview
  11.3.5 Empire Genomics Latest Developments
11.4 SeraCare Life Sciences
  11.4.1 SeraCare Life Sciences Company Information
  11.4.2 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.4.3 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 SeraCare Life Sciences Main Business Overview
  11.4.5 SeraCare Life Sciences Latest Developments
11.5 F. Hoffmann-La Roche
  11.5.1 F. Hoffmann-La Roche Company Information
  11.5.2 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.5.3 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 F. Hoffmann-La Roche Main Business Overview
  11.5.5 F. Hoffmann-La Roche Latest Developments
11.6 NeoGenomics Laboratories
  11.6.1 NeoGenomics Laboratories Company Information
  11.6.2 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.6.3 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 NeoGenomics Laboratories Main Business Overview
  11.6.5 NeoGenomics Laboratories Latest Developments
11.7 Glaxosmithkline
  11.7.1 Glaxosmithkline Company Information
  11.7.2 Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.7.3 Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Glaxosmithkline Main Business Overview
  11.7.5 Glaxosmithkline Latest Developments
11.8 OncoDNA
  11.8.1 OncoDNA Company Information
  11.8.2 OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.8.3 OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 OncoDNA Main Business Overview
  11.8.5 OncoDNA Latest Developments
11.9 Merck & Co.
  11.9.1 Merck & Co. Company Information
  11.9.2 Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.9.3 Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 Merck & Co. Main Business Overview
  11.9.5 Merck & Co. Latest Developments
11.10 Daiichi Sankyo
  11.10.1 Daiichi Sankyo Company Information
  11.10.2 Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.10.3 Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.10.4 Daiichi Sankyo Main Business Overview
  11.10.5 Daiichi Sankyo Latest Developments
11.11 S Deciphera Pharmaceuticals
  11.11.1 S Deciphera Pharmaceuticals Company Information
  11.11.2 S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  11.11.3 S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2025)
  11.11.4 S Deciphera Pharmaceuticals Main Business Overview
  11.11.5 S Deciphera Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. NTRK Fusion Gene Positive Advanced Solid Tumor Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Therapeutics
Table 4. Major Players of Diagnostics
Table 5. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025) & ($ millions)
Table 7. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2020-2025)
Table 8. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025) & ($ millions)
Table 10. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2020-2025)
Table 11. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Player (2020-2025) & ($ millions)
Table 12. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Player (2020-2025)
Table 13. NTRK Fusion Gene Positive Advanced Solid Tumor Key Players Head office and Products Offered
Table 14. NTRK Fusion Gene Positive Advanced Solid Tumor Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025) & ($ millions)
Table 18. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region (2020-2025)
Table 19. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Country (2020-2025)
Table 23. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2020-2025)
Table 25. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2020-2025)
Table 27. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region (2020-2025)
Table 29. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Country (2020-2025)
Table 33. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of NTRK Fusion Gene Positive Advanced Solid Tumor
Table 39. Key Market Challenges & Risks of NTRK Fusion Gene Positive Advanced Solid Tumor
Table 40. Key Industry Trends of NTRK Fusion Gene Positive Advanced Solid Tumor
Table 41. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Bayer Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 46. Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 47. Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Bayer Main Business
Table 49. Bayer Latest Developments
Table 50. Teva Pharmaceuticals Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 51. Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 52. Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Teva Pharmaceuticals Main Business
Table 54. Teva Pharmaceuticals Latest Developments
Table 55. Empire Genomics Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 56. Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 57. Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Empire Genomics Main Business
Table 59. Empire Genomics Latest Developments
Table 60. SeraCare Life Sciences Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 61. SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 62. SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. SeraCare Life Sciences Main Business
Table 64. SeraCare Life Sciences Latest Developments
Table 65. F. Hoffmann-La Roche Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 66. F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 67. F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. F. Hoffmann-La Roche Main Business
Table 69. F. Hoffmann-La Roche Latest Developments
Table 70. NeoGenomics Laboratories Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 71. NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 72. NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. NeoGenomics Laboratories Main Business
Table 74. NeoGenomics Laboratories Latest Developments
Table 75. Glaxosmithkline Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 76. Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 77. Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Glaxosmithkline Main Business
Table 79. Glaxosmithkline Latest Developments
Table 80. OncoDNA Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 81. OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 82. OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. OncoDNA Main Business
Table 84. OncoDNA Latest Developments
Table 85. Merck & Co. Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 86. Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 87. Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Merck & Co. Main Business
Table 89. Merck & Co. Latest Developments
Table 90. Daiichi Sankyo Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 91. Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 92. Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. Daiichi Sankyo Main Business
Table 94. Daiichi Sankyo Latest Developments
Table 95. S Deciphera Pharmaceuticals Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 96. S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 97. S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 98. S Deciphera Pharmaceuticals Main Business
Table 99. S Deciphera Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. NTRK Fusion Gene Positive Advanced Solid Tumor Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. NTRK Fusion Gene Positive Advanced Solid Tumor Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. NTRK Fusion Gene Positive Advanced Solid Tumor Sales Market Share by Country/Region (2024)
Figure 8. NTRK Fusion Gene Positive Advanced Solid Tumor Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type in 2024
Figure 10. NTRK Fusion Gene Positive Advanced Solid Tumor in Hospitals and Clinics
Figure 11. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market: Hospitals and Clinics (2020-2025) & ($ millions)
Figure 12. NTRK Fusion Gene Positive Advanced Solid Tumor in Cancer Centers
Figure 13. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market: Cancer Centers (2020-2025) & ($ millions)
Figure 14. NTRK Fusion Gene Positive Advanced Solid Tumor in Others
Figure 15. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market: Others (2020-2025) & ($ millions)
Figure 16. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application in 2024
Figure 17. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Player in 2024
Figure 18. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region (2020-2025)
Figure 19. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2020-2025 ($ millions)
Figure 20. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2020-2025 ($ millions)
Figure 21. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2020-2025 ($ millions)
Figure 23. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Value Market Share by Country in 2024
Figure 24. United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region in 2024
Figure 29. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2020-2025)
Figure 30. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2020-2025)
Figure 31. China NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 35. India NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Country in 2024
Figure 38. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2020-2025)
Figure 39. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2020-2025)
Figure 40. Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 41. France NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 42. UK NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2020-2025)
Figure 48. Egypt NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 54. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 55. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 57. United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 58. Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 59. Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 60. Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 61. China NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 62. Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 63. Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 65. India NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 66. Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 67. Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 68. France NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 69. UK NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 70. Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 71. Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 72. Egypt NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 73. South Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 74. Israel NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 75. Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)
Figure 76. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2026-2031 ($ millions)